Clinical significance of pAKT and CD44v6 overexpression with breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 8, 2010, Pages 1283-1292

  Yu, Pei ^a   Zhou, Ling ^a   Ke, Weifeng ^a   Li, Ke ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Breast cancer; CD44v6; HER2; PAKT

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V6 ANTIGEN; PROTEIN KINASE B; HERMES ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BREAST TUMOR; CANCER STAGING; FEMALE; FOLLOW UP; GENETICS; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ANTIGENS, CD44; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL RATE;

EID: 77954601345     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0779-x     Document Type: Article

References (40)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-3988 (Pubitemid 36418143)
2. Andre F, Nahta R, Conforti R et al (2008) Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19(2):315-320
3. Ayroldi E, Cannarile L, Migliorati G et al (1995) CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 86(7):2672-2678
4. Bates RC, Elith CA, Thorne RF et al (1998) Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line. Cell Adhes Commun 6(1):21-38
5. Berner HS, Suo Z, Risberg B et al (2003) Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42(6):546-554
6. Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18(4):251-259
7. Bourguignon LY, Singleton PA, Zhu H et al (2003) Hyaluronanmediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage- colony stimulating factor) production and breast tumor progression. J Biol Chem 278(32):29420-29434
8. Chalhoub N, Baker SJ (2009) PTEN and the PI3-Kinase pathway in Cancer. Annu Rev Pathol 4:127-150
9. Franke TF, Kaplan DR, Cantley LC (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88(4):435-437
10. Friedrichs K, Franke F, Lisboa BW et al (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55(22):5424-5433
11. Ghatak S, Misra S, Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277(41):38013-38020
12. Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13-24
13. Gunthert AR, Strater J, von Reyher U et al (1996) Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol 134(4):1089-1096 (Pubitemid 26278230)
14. Herrera-Gayol A, Jothy S (1999) Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol 66(2):149-156
15. Herrlich P, Zoller M, Pals ST et al (1993) CD44 splice variants: metastases meet lymphocytes. Immunol Today 14(8):395-399
16. Hudson DL, Sleeman J, Watt FM (1995) CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci 108(Pt 5):1959-1970
17. Jansen RH, Joosten-Achjanie SR, Arends JW et al (1998) CD44v6 is not a prognostic factor in primary breast cancer. Ann Oncol 9(1):109-111
18. Janssen EA, Soiland H, Skaland I et al (2007) Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged\55 years. Cell Oncol 29(1):25-35
19. Jones PF, Jakubowicz T, Hemmings BA (1991) Molecular cloning of a second form of rac protein kinase. Cell Regul 2(12):1001-1009
20. Kamikura DM, Khoury H, Maroun C et al (2000) Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Mol Cell Biol 20(10):3482-3496
21. Katso R, Okkenhaug K, Ahmadi K et al (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615-675
22. Kaufmann M, Heider KH, Sinn HP et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345(8950):615-619
23. Kim Y, Lee YS, Choe J et al (2008) CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283(33):22513-22528
24. Klingbeil P, Marhaba R, Jung T et al (2009) CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 7(2):168-179
25. Knuefermann C, Lu Y, Liu B et al (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21):3205-3212
26. Lee JL, Wang MJ, Sudhir PR et al (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67(5):2089-2097
27. Lester BR, McCarthy JB (1992) Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion and metastasis. Cancer Metastasis Rev 11(1):31-44
28. Ma W, Deng Y, Zhou L (2005) The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol (R Coll Radiol) 17(4):258-263
29. Marhaba R, Freyschmidt-Paul P, Zoller M (2006) In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol 36(11):3017-3032
30. Modi S, DiGiovanna MP, Lu Z et al (2005) Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 23(6):483-487
31. Sarbassov DD, Guertin DA, Ali SM et al (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098-1101
32. Schmitz KJ, Otterbach F, Callies R et al (2004) Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17(1):15-21
33. Stal O, Perez-Tenorio G, Akerberg L et al (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5(2):R37-R44
34. Subramaniam V, Vincent IR, Gardner H et al (2007) CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 83(2):207-215
35. Sun M, Wang G, Paciga JE et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159(2):431-437
36. Tokunaga E, Kataoka A, Kimura Y et al (2006a) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42(5):629-635
37. Tokunaga E, Kimura Y, Oki E et al (2006b) Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118(2):284-289
38. Tulasne D, Foveau B (2008) The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 15(3):427-434
39. Wu Y, Mohamed H, Chillar R et al (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10(1):R3
40. Zhou X, Tan M, Stone Hawthorne V et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779-6788